There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), Longeveron (LGVN – Research Report) and EDAP TMS (EDAP – Research Report) with bullish sentiments.
Arvinas Holding Company (ARVN)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Arvinas Holding Company, with a price target of $87.00. The company’s shares closed last Thursday at $32.11.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
Currently, the analyst consensus on Arvinas Holding Company is a Strong Buy with an average price target of $65.25, implying a 92.6% upside from current levels. In a report issued on May 8, Wedbush also initiated coverage with a Buy rating on the stock with a $57.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Longeveron (LGVN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Longeveron today and set a price target of $12.00. The company’s shares closed last Thursday at $1.29, close to its 52-week low of $1.24.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Longeveron has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
EDAP TMS (EDAP)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on EDAP TMS today and set a price target of $19.00. The company’s shares closed last Thursday at $6.89.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
Currently, the analyst consensus on EDAP TMS is a Strong Buy with an average price target of $12.67, implying an 82.6% upside from current levels. In a report issued on May 15, Lake Street also reiterated a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARVN:
- Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
- Arvinas,Pfizer update Phase 1b data on vepdegestrant palbociclib combination
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
- Jefferies retail/healthcare analysts to hold an analyst/industry conference call
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
